NEW YORK August 4, 2025 Noom, the leading digital healthcare company committed to chronic disease prevention and empowering people to live better longer, today announced the launch of the Noom Microdose GLP-1 Rx Program, a groundbreaking offering designed to unlock weight loss and long-term health benefits while minimizing side effects through personalized microdoses of GLP-1 medication, when clinically appropriate
Exposure to insulin is indicated to facilitate the removal of A in astrocytes through increased expression of IDE [150]
335,336 Further, the GLP-1/GIP dual-agonist tested in this study, MAR709, lost its superior efficacy on body weight and food intake over GLP-1 in the CNS-GIPR knockout mice, suggesting that this dual-agonist mediates part of its action via the CNS-GIPR
I understand that, I really do, but it is hard to read comments on social media where its clear that many consumers have no idea what they are actually buying